Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study

被引：0
|
作者：
Taylor, P. [1 ]
Genovese, M. [2 ]
Keystone, E. [3 ]
Schlichting, D. [4 ]
Beattie, S. [5 ]
Macias, W. [4 ]
Lundmark, J. [6 ]
机构：
[1] Univ Oxford, Kennedy Inst Rheumatol, Oxford OX1 2JD, England
[2] Stanford Univ, Immunol & Rheumatol Clin, Stanford, CA 94305 USA
[3] Mt Sinai Hosp, Rebecca MacDonald Ctr Arthrit & Autoimmune Dis, Toronto, ON M5G 1X5, Canada
[4] Eli Lilly & Co, Corp Ct, Indianapolis, IN 46285 USA
[5] Eli Lilly & Co, Global Stat Sci Autoimmune Platform, Indianapolis, IN USA
[6] Eli Lilly Sweden AB, Biomed, Solna, Sweden
来源：
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY | 2014年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP201
引用
收藏
页码：59 / 59
页数：1
相关论文
共 50 条
  • [1] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, P.
    Genovese, M. C.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 65 - 66
  • [2] BARICITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN AN OPEN-LABEL, LONG-TERM EXTENSION STUDY
    Taylor, Peter
    Genovese, Mark
    Keystone, Ed
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : A31 - A31
  • [3] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [4] Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Wood, Susan P.
    Terry, Ketti K.
    Nakamura, Hiroyuki
    Ohno, Yukako
    Gruben, David
    Benda, Birgitta
    Wang, Lisy
    Riese, Richard
    [J]. ARTHRITIS AND RHEUMATISM, 2013, 65 : S993 - S993
  • [5] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy up to 48 Months
    Wollenhaupt, Jurgen
    Silverfield, Joel C.
    Lee, Eun Bong
    Wood, Susan P.
    Soma, Koshika
    Wang, Lisy
    Nakamura, Hiroyuki
    Komuro, Yoshihiro
    Nduaka, Chudi I.
    Gruben, David
    Benda, Birgitta
    Zwillich, Samuel H.
    Riese, Richard
    Bradley, John D.
    [J]. ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S548 - S549
  • [6] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, FOR THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION UP TO 6 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K. K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 259 - 259
  • [7] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years.
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Wood, S. P.
    Terry, K.
    Nakamura, H.
    Kwok, K.
    Anisfeld, A.
    Nduaka, C.
    Riese, R.
    Wang, L.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S375 - S375
  • [8] Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension Studies over 9 Years
    Wollenhaupt, Juergen
    Silverfield, Joel
    Lee, Eun Bong
    Terry, Ketti
    Kwok, Kenneth
    Strengholt, Sander
    DeMasi, Ryan
    Wang, Lisy
    [J]. ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [9] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 8 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K.
    Kwok, K.
    Abramsky, S.
    Wang, M.
    Nduaka, C.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 277 - 278
  • [10] TOFACITINIB, AN ORAL JANUS KINASE INHIBITOR, IN THE TREATMENT OF RHEUMATOID ARTHRITIS: SAFETY AND EFFICACY IN OPEN-LABEL, LONG-TERM EXTENSION STUDIES OVER 9 YEARS
    Wollenhaupt, J.
    Silverfield, J.
    Lee, E. B.
    Terry, K.
    Kwok, K.
    Strengholt, S.
    DeMasi, R.
    Wang, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 978 - 978
12345